GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. The National Cancer Institute has indicated that cell therapies could eventually become the standard of care in the multi-billion market to treat cancer. Juno Therapeutics Inc, another...

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market T-cell therapies for HPV-associated cancers. T-cell receptors are a class of compounds that make it easier for the body's immune cells to mainly identify and then destroy cancer cells. Human papillomavirus is the most common viral infection of...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Microbiome studies changing human health Friday, 19 Jun 2015 | 8:33 AM ET
    Microbiome changing human health

    CNBC's Meg Tirrell explains what the microbiome is and why it's medicines new frontier.

  • Gilead still has China patent for active compound. NEW YORK/ SHANGHAI, June 19- China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment. Gilead, however, holds the China patent to the base...

  • June 19- China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which...

  • Insurer mergers may be 'dangerous': Mt. Sinai CEO Thursday, 18 Jun 2015 | 6:05 PM ET
    Signage hangs outside Mount Sinai Hospital on August 4, 2014 in New York City.

    Consolidation in the health insurance industry is "potentially dangerous" for the hospital business, Mount Sinai Health System's CEO said Thursday.

  • June 18- Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy. The U.S. Food and Drug Administration approved Vectibix in 2006 as a standalone treatment for metastatic colorectal cancer. Colorectal cancer affects about 1.2 million people worldwide each year,...

  • TEVA PHARMACEUTICALS' PATENT ON MULTIPLE SCLEROSIS DRUG INVALID, U.S.

  • Health dangers in buying online breast milk: study Thursday, 18 Jun 2015 | 10:25 AM ET

    Those who buy human breast milk via unregulated online sites are opening themselves to risk of disease including HIV, a U.K. study has found.

  • Tom Brokaw: I am in remission, I feel quite good Thursday, 18 Jun 2015 | 7:31 AM ET
    Tom Brokaw: I am in remission, I feel quite good

    Fmr. NBC Nightly News Anchor Tom Brokaw, shares his greatest life lessons and biggest surprises, after the diagnosis and treatment for multiple myeloma, which is an incurable but treatable cancer.

  • *Guinea trial last chance to show vaccine efficacy. LONDON, June 17- Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. The haemorrhagic Ebola virus has killed more than 11,000 people in Guinea, Sierra Leone and Liberia in an...

  • June 17- Synergy Pharmaceuticals Inc said its drug for idiopathic constipation met the main goal in a late-stage trial, sending its shares up 56 percent in premarket trade on Wednesday. Idiopathic constipation affects about 15 percent of the U.S. population, according to the National Institutes of Health. Only two drugs are currently approved to treat the...

  • $180 million discovery from the placenta Wednesday, 17 Jun 2015 | 6:50 AM ET
    $180 million discovery from the placenta

    Biotech MiMedx sells amniotic membrane tissue that is used to help wounds heal 2-3 times faster than standard care. MiMedx CEO Pete Petit, discusses the effective tissue developed from the placenta.

  • Are India's medical schools broken? Tuesday, 16 Jun 2015 | 8:37 PM ET

    India's system for training doctors is plagued by fraud and unprofessional teaching practices, worsening public health issues, Reuters reports.

  • The 'Godfather of cannabis research' speaks out Monday, 15 Jun 2015 | 11:30 AM ET
    The 'Godfather of cannabis research' speaks out

    CNBC's Dina Gusovsky sits down with Dr. Raphael Mechoulam in Israel to discuss the current and future state of the medical marijuana industry and how big pharmaceutical companies might be able to benefit.

  • How Israel is leading the medical marijuana industry Monday, 15 Jun 2015 | 11:30 AM ET
    How Israel is leading the medical marijuana industry

    CNBC got exclusive access to a children's oncology unit and nursing home in Israel that allows children and elderly to consume medical marijuana on-site. Now, the U.S. and Israel plan to expand a marijuana partnership that dates back decades. CNBC's Dina Gusovsky reports.

  • Medical marijuana coming to New York state Monday, 15 Jun 2015 | 6:46 AM ET
    Medical marijuana coming to New York state

    New Yorkers suffering from cancer, epilepsy, Crohn's disease and Parkinson's disease may soon be able to access medical marijuana in the state. Jason Cranford, expert botanist and Director of Cultivation at the Compassionate Care Center of New York, provides insight.

  • LONDON, June 13- A pioneering gene therapy for sickle cell disease is working well so far for a 13- year-old French boy with the hereditary blood disorder, researchers said on Saturday, in a boost for the technology to fix faulty genes. He is the first patient with severe sickle cell disease to be treated with Bluebird Bio's LentiGlobin BB305 product, which the U.S....

  • June 12- The U.S. Food and Drug Administration said it approved a brain implant from St. Jude Medical Inc that helps reduce symptoms of Parkinson's disease and essential tremor, a neurological disorder that causes rhythmic shaking. The device can be used when medication alone may not provide adequate relief from symptoms such as walking difficulties, balance...